Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended		15 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012
Costs and expenses:
Noncash stock expense associated with in-licensing agreement	$ 0	$ 297,000	$ 16,578,000	$ 297,000	$ 16,875,000
Noncash compensation	109,198		109,198		109,198
Other research and development	1,536,896	0	1,700,249	0	1,730,532
Total research and development	1,646,094	297,000	18,387,447	297,000	18,714,730
General and administrative:
Noncash compensation	1,062,793	0	1,251,302	0	1,337,796
Other general and administrative	396,043	0	851,535	0	1,319,732
Total general and administrative	1,458,836	0	2,102,837	0	2,657,528
Total costs and expenses	3,104,930	297,000	20,490,284	297,000	21,372,258
Operating loss	(3,104,930)	(297,000)	(20,490,284)	(297,000)	(21,372,258)
Other (income) expense:
Interest income	(4,092)	0	(7,760)	0	(7,760)
Other income	(272,232)	0	(272,232)	0	(272,232)
Interest expense	228,109	0	448,258	0	455,355
Change in fair value of notes payable	(482,556)	0	(687,853)	0	(687,853)
Total other (income)	(530,771)	0	(519,587)	0	(512,490)
Consolidated net loss	(2,574,159)	(297,000)	(19,970,697)	(297,000)	(20,859,768)
Net loss attributable to noncontrolling interest	(679,506)	(14,895)	(7,819,954)	(14,895)	(7,855,951)
Net loss attributable to TG Therapeutics, Inc. and subsidiaries	$ (1,894,653)	$ (282,105)	$ (12,150,743)	$ (282,105)	$ (13,003,817)
Basic and diluted net loss per common share (in dollars per share)	$ (0.16)	$ (0.15)	$ (1.44)	$ (0.31)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	11,777,563	1,822,154	8,419,481	916,110